SCHEMBL4194699

SCHEMBL4194699

CCCN1CC[C@@H](c2ccc(NS(=O)(=O)c3cccc(Cl)c3)cc2)C1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PGR P06401 7/20 0.52
DRD2 P14416 6/20 0.49
DRD3 P35462 4/20 0.49
SIGMAR1 Q99720 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
PKM P14618 1/20 0.47
CCR5 P51681 1/20 0.47
HTR1A P08908 1/20 0.46
HTR1D P28221 1/20 0.46
HTR1B P28222 1/20 0.46
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46
HTR1F P30939 1/20 0.46
HTR7 P34969 1/20 0.46
HTR6 P50406 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4194704 1.00 PGR (0.52) PGRDRD2DRD3SIGMAR1LMNA
SCHEMBL4193927 0.92 PGR (0.57) PGRDRD3LMNAMAPTTDP1
SCHEMBL1546647 0.88 DRD2 (0.58) DRD2DRD3LMNAMAPTTDP1
SCHEMBL1546645 0.88 DRD2 (0.58) DRD2DRD3LMNAMAPTTDP1
SCHEMBL4198378 0.88 DRD2 (0.53) PGRDRD2DRD3SIGMAR1HTR1A
SCHEMBL4198379 0.88 DRD2 (0.53) PGRDRD2DRD3SIGMAR1HTR1A
SCHEMBL1546115 0.85 DRD2 (0.55) PGRDRD2DRD3SIGMAR1LMNA
SCHEMBL4190597 0.85 DRD2 (0.49) DRD2DRD3SIGMAR1LMNA
SCHEMBL4190601 0.85 DRD2 (0.49) DRD2DRD3SIGMAR1LMNA
SCHEMBL1546113 0.85 DRD2 (0.55) PGRDRD2DRD3SIGMAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642642-B2 Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor ABBOTT LABORATORIES (US) 2014-02-04 US disclosed
US-20090306175-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2009-12-10 US disclosed
EP-2029528-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-03-04 EP disclosed
WO-2007118899-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306175-A1 HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR HTR6, HTR1A, HTR5A PGR 492/4885DRD2 116/4885DRD3 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.